Co-Diagnostics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Co-Diagnostics han disminuido a una tasa media anual de -56.6%, mientras que en la industria Medical Equipment los beneficios crecieron en un 15.3% anualmente. Los ingresos han ido disminuyendo a una tasa media de 68.2% al año.
Información clave
-56.64%
Tasa de crecimiento de los beneficios
-55.05%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 8.90% |
| Tasa de crecimiento de los ingresos | -68.23% |
| Rentabilidad financiera | -302.34% |
| Margen neto | -6,753.69% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Oct 18
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Narrative Update on Co-Diagnostics Analysts have marginally increased their price target for Co-Diagnostics from $3.00 to $3.00, citing minimal changes in valuation inputs and updated financial forecasts as the rationale for this slight adjustment. What's in the News Announced development of a proprietary sample preparation instrument to streamline its point-of-care Co-Dx PCR Mycobacterium Tuberculosis Test.Actualización de narrativa • Oct 04
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Analysts have significantly lowered their price target for Co-Diagnostics from $10.00 to $3.00, citing revised fair value estimates and a reduced expectation for future earnings multiples. What's in the News Co-Diagnostics completed a $3.85 million Follow-on Equity Offering, issuing 9,619,000 shares of common stock at $0.40 per share in a registered direct offering.
Nueva narrativa • May 04
Co-Dx PCR Platform And FDA 510(K) Clearance Will Expand Market Reach
Advancements in PCR platform and manufacturing enhance commercialization, potentially increasing revenues and profit margins through scale efficiencies.Artículo de análisis • Feb 25
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Artículo de análisis • Jun 14
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • May 18
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
One thing we could say about the covering analyst on Co-Diagnostics, Inc. ( NASDAQ:CODX ) - they aren't optimistic...Artículo de análisis • Apr 14
A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Key Insights Co-Diagnostics' estimated fair value is US$1.40 based on 2 Stage Free Cash Flow to Equity Current share...Seeking Alpha • Sep 07
Co-Diagnostics: Hold Thesis Remains Well Intact
Summary We reiterate the hold thesis on Co-Diagnostics following Q2 FY22 earnings. Covid-19 turnover continues to diminish for CODX whilst surging for rival test providers. Inventory levels for the company spiked year over year as the Omicron-led demand in testing faded. We've valued CODX at $3.24 suggesting shares are adequately priced by the market consensus. From the Portfolio Manager's Desk Having witnessed the rapid cooling of Omicron-led demand in Covid-19 diagnostics, the Sars-CoV-2 assay market is looking increasingly unattractive. Here revisit Co-Diagnostics, Inc. (CODX) a name that we are extremely familiar with having tracked the company across the entire span of the pandemic. We were buyers of the stock in January FY21 as a speculative position built around our core holdings in med-tech. We've since exited the position with a small loss, and believe impeding macro-headwinds remain for the company. With Covid-assay demand still diminishing, supplier inventory levels are likely at historically low levels, and the question is if they will seek to restore/repurchase inventory levels back to FY21 highs. The bulk of CODX's turnover is derived from Covid-19, so this is key to the investment debate for CODX looking ahead. Investment Thesis Summary Here we reiterate a hold rating on CODX with a $3.24 price target. With Covid-19 test revenue diminishing substantially in Q2 FY22 [whilst rival test makers revenue surged YoY] there is low predictability of the company's future cash flows by estimation. Valuations are supportive of a neutral view and forward looking earnings are marred by the fact Covid-19 test volumes will likely dwindle as time goes on. Although it has other innovations in the pipeline, the timing and timeline for these are fluid for now and there's no concrete launch dates. We need further clarity on how CODX intends to distribute its top-line ex-Covid. Rate hold price target $3.24. Co-Diagnostics' Q2 earnings illustrate headwinds CODX came in with a fairly weak set of numbers when compared to Q2 FY21. It clipped revenue of just $5 million ("mm"), an 81.6% YoY decrease from $27.4mm the year prior. The substantial tightening at the top line came as demand for CODX's Logix Smart Covid-19 test, that was developed in response to the pandemic [more on this later]. CODX also recognized a 54% YoY decline in sales to third parties of ~$75,000. Quarterly gross profit margin narrowed by 9 percentage points to 81.8% following the tighter revenue and unit volumes whilst fixed production costs made up a larger portion of revenues. Moving down the P&L, OPEX also narrowed by ~36% YoY to $8.3mm secondary to lower variable expenditures tied to sales volume. Quarterly operating loss came in at $4.17mm down from a profit of ~$11.8mm the year prior, again from the lower revenues and a $353,000 YoY gain in depreciation and amortization expense. Meanwhile R&D investment for the quarter came in 16.7% lower to $3.9mm from a relatively high base in Q2 FY21, and the company also bought back $2.6mm of its own stock. It brought this down to a quarterly net loss of ~$2.7mm or -$0.08/share, down from a $9.7mm/ $0.34 per share after-tax profit last year. CODX did still see profitability from CFFO during the quarter. In fact, for the 6-months to Q2 FY22, it printed $9.4mm [$0.28/share] in cash from operations. However, also noted is that it added $2.9mm stock based compensation expense to this, whereas accounts receivable value jumped $8.56mm during this time. Free cash flow ("FCF") has narrowed on a sequential basis for the company and came in at $1.15mm for the quarter and $25.2mm for the TTM. However, one point to note is that its TTM return on invested capital ("ROIC") has remained in the double digits at 24.2% last quarter and comfortably covers CODX's WACC hurdle of ~6.2% by ~4 turns. As seen in Exhibit 1, ROIC has remained consistently high whilst FCF is reinvested heavily back into the business. Exhibit 1. Quarterly FCF continues to decline whilst TTM ROIC remains buoyant, albeit tightening as well. This adds a bullish tilt to the risk/reward calculus and provides a solid bedrock for the company to continue seeing return on its investments looking ahead. Data: HB Insights, CODX SEC Filings Outlook weakened on lower test demand As have previously outlined, Covid-19 provided CODX with stellar revenue and earnings leverage that was reflected in its numbers at the time. Previously, we advocated that CODX's test volumes should remain high as there was currently no test to distinguish between influenza and Covid-19, a tailwind for assay kit producers. Management remain equally as optimistic, per language from CEO Dwight Egan on the Q2 earnings call: This dramatic shift [decrease] in testing behavior was widely felt across the diagnostics industry. Experts believe other waves of COVID variants are all, but inevitable. However, the timing and severity are impossible to predict with every new variant, including the possibility of immune escape as variants and sub-variants by for dominance. In the U.S. alone, we are still seeing around a 100,000 new COVID cases reported per day, over 6,000 COVID-related hospital admissions and nearly 400 deaths, all evidence to date points to a resilient mutable virus with no indication it will go away and that we will be living with it for years to come." Clearly, however, the Omicron-led demand for assay volumes has subsided and this is reflected in inventory values of both manufacturers and suppliers of the tests. We see evidence of this in CODX's numbers as its inventory value increased ~135% YoY in the second quarter to $4.7mm.Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Co-Diagnostics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 1 | -49 | 11 | 20 |
| 31 Dec 25 | 1 | -47 | 11 | 19 |
| 30 Sep 25 | 1 | -32 | 16 | 19 |
| 30 Jun 25 | 1 | -36 | 19 | 19 |
| 31 Mar 25 | 3 | -36 | 20 | 20 |
| 31 Dec 24 | 4 | -38 | 21 | 21 |
| 30 Sep 24 | 7 | -41 | 20 | 22 |
| 30 Jun 24 | 9 | -38 | 20 | 23 |
| 31 Mar 24 | 7 | -39 | 21 | 24 |
| 31 Dec 23 | 7 | -35 | 21 | 23 |
| 30 Sep 23 | 5 | -43 | 22 | 22 |
| 30 Jun 23 | 7 | -38 | 22 | 21 |
| 31 Mar 23 | 12 | -32 | 21 | 19 |
| 31 Dec 22 | 34 | -14 | 22 | 17 |
| 30 Sep 22 | 53 | 15 | 20 | 15 |
| 30 Jun 22 | 78 | 28 | 22 | 16 |
| 31 Mar 22 | 101 | 40 | 26 | 17 |
| 31 Dec 21 | 98 | 37 | 25 | 15 |
| 30 Sep 21 | 105 | 42 | 25 | 14 |
| 30 Jun 21 | 96 | 46 | 21 | 9 |
| 31 Mar 21 | 93 | 51 | 15 | 5 |
| 31 Dec 20 | 75 | 42 | 13 | 3 |
| 30 Sep 20 | 48 | 28 | 9 | 2 |
| 30 Jun 20 | 26 | 10 | 7 | 2 |
| 31 Mar 20 | 2 | -6 | 5 | 1 |
| 31 Dec 19 | 0 | -6 | 5 | 1 |
| 30 Sep 19 | 0 | -6 | 5 | 1 |
| 30 Jun 19 | 0 | -6 | 5 | 1 |
| 31 Mar 19 | 0 | -6 | 5 | 1 |
| 31 Dec 18 | 0 | -6 | 5 | 1 |
| 30 Sep 18 | 0 | -6 | 5 | 1 |
| 30 Jun 18 | 0 | -8 | 5 | 1 |
| 31 Mar 18 | 0 | -8 | 4 | 1 |
| 31 Dec 17 | 0 | -7 | 4 | 1 |
| 30 Sep 17 | 0 | -6 | 3 | 1 |
| 30 Jun 17 | 0 | -3 | 1 | 1 |
| 31 Mar 17 | 0 | -2 | 1 | 1 |
| 31 Dec 16 | 0 | -2 | 1 | 1 |
| 30 Sep 16 | 0 | -2 | 1 | 1 |
| 31 Dec 15 | 0 | -2 | 1 | 1 |
Ingresos de calidad: CODX actualmente no es rentable.
Margen de beneficios creciente: CODX actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CODX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 56.6% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CODX en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: CODX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (14.8%).
Rentabilidad financiera
Alta ROE: CODX tiene una rentabilidad financiera negativa (-302.34%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/14 23:54 |
| Precio de las acciones al final del día | 2026/06/12 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Co-Diagnostics, Inc. está cubierta por 2 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jason McCarthy | Maxim Group |
| James Sidoti | Sidoti & Company, LLC |